ADAMTS13 and hemolytic-uremic syndrome: As the delivery of the result of ADAMTS13 activity in our patient was delayed, we initially introduced Caplacizumab and plasmapheresis, however, treatment for HUS primarily involves supportive care, including hemodialysis if necessary, and specific antibiotic therapy, whereas plasmapheresis is usually not effective.[6] Understanding the distinctions between these 2 conditions is crucial, especially in cases of Capnocytophaga canimorsus sepsis, where the onset of thrombotic microangiopathy requiring immediate intervention may occur before bacteriological culture results are available.